NCT05033964View on ClinicalTrials.gov

The DESyne BDS Plus RCT: A Randomized Clinical Trial to Assess the Elixir DESyne BDS Plus Drug Eluting Coronary Stent System for the Treatment of de Novo Native Coronary Artery Lesions

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

December 15, 2021

Primary Completion Date

December 2, 2022

Study Completion Date

March 31, 2026

Conditions
Coronary Artery Disease
Interventions
COMBINATION_PRODUCT

Percutaneous Coronary Intervention with drug eluting stents

Coronary drug eluting stent implantation

Trial Locations (14)

1023

Auckland City Hospital, Auckland

2020

ZNA Middelheim, Antwerp

2025

Middlemore Hospital, Auckland

3000

Universitaire Ziekenhuizen Leuven, Leuven

3240

Waikato Hospital, Hamilton

3600

Ziekenhuis Oost-Limburg, Campus Sint Jan, Genk

8000

AZ Sint Jan Brugge Oostende AV, Bruges

8011

Christchurch Hospital, Christchurch

9016

Dunedin Hospital, Dunedin

12808

General University Hospital, Prague

04012-909

Instituto Dante Pazzanese, São Paulo

05403

Instituto do Coração da Faculdade, São Paulo

5623 EJ

Catharina Hospital, Eindhoven

0622

North Shore Hospital, Auckland

Sponsors
All Listed Sponsors
lead

Elixir Medical Corporation

INDUSTRY

NCT05033964 - The DESyne BDS Plus RCT: A Randomized Clinical Trial to Assess the Elixir DESyne BDS Plus Drug Eluting Coronary Stent System for the Treatment of de Novo Native Coronary Artery Lesions | Biotech Hunter | Biotech Hunter